Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study
Cerebrovascular Diseases · 24.04.2026 · 1-9
DOI: 10.1159/000552209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cerebrovascular Diseases, online erschienen am 24.04.2026. Verfasst von Georgeio Sader und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Neurovascular Surgery, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
Limited longitudinal data exist regarding functional and patient-reported outcome (PRO) in symptomatic hemorrhage (SH) from cerebral cavernous malformation enrolled in clinical trials.
Methods
We assessed functional outcome using the modified Rankin Scale (mRS) and NIH Stroke Scale (NIHSS), and PRO using European Quality of Life 5-Dimension and Visual Analog Scale (EQ-5D-3L and VAS) and PRO-measurement information system (PROMIS-29) at baseline, 1 year, and 2 years in patients randomized to atorvastatin and placebo in the prospective, double-blinded Atorvastatin Treatment of Cavernous Angioma Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) trial. Sensitivity analyses compared score change in cases with and without prospective SH and in those with or without a ≥6% increase in lesional iron content on quantitative susceptibility mapping (QSM), consistent with occult bleeding.
Results
Of 64 patients with paired QSM and outcome data, baseline characteristics were similar; baseline mRS distributions differed between groups but were similar at years 1 and 2. No significant differences in functional and PRO appeared between the atorvastatin and placebo groups. While there was a decline in PROMIS-29 sleep disturbance (57.1% SH vs. 7.7% no SH; p < 0.01), fatigue (57.1% SH vs. 21.2% no SH; p = 0.06), and social role (44.4% SH vs. 16% no SH; p = 0.07) domains with prospective SH over 2 years, the small numbers of patients limit the generalizability. These functional and PRO declines were generally specific but poorly sensitive for identifying SH or occult bleeding.
Discussion
Despite more frequently reported side effects with atorvastatin in the trial, there were no significant differences in functional or PRO in the atorvastatin and placebo groups. Functional and PRO decline were highly specific but poorly sensitive for identifying prospective SH or occult bleeding.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Neurovascular Surgery, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
- BIOS Clinical Trial Coordinating Center and the Trial Innovation Center, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA, flemming.kelly@mayo.edu.
Förderung
- NINDS NIH HHS
Zitieren
APA
Sader, G., Alcazar-Felix, R. J., Jhaveri, A., Ali, B., Stadnik, A., Lee, J., Shenkar, R., Treine, K., McBee, N., Girard, R., Thompson, R. E., Hanley, D. F., Awad, I., & Flemming, K. D. (2026). Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study. Cerebrovascular Diseases, 1-9. https://doi.org/10.1159/000552209
Vancouver
Sader G, Alcazar-Felix RJ, Jhaveri A, Ali B, Stadnik A, Lee J, et al. Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study. Cerebrovascular Diseases. 2026:1-9. doi:10.1159/000552209
BibTeX
@article{Sader2026,
author = {Sader, Georgeio and Alcazar-Felix, Roberto J and Jhaveri, Aditya and Ali, Bader and Stadnik, Agnieszka and Lee, Justine and Shenkar, Robert and Treine, Kevin and McBee, Nichol and Girard, Romuald and Thompson, Richard E and Hanley, Daniel F and Awad, Issam and Flemming, Kelly D},
title = {Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study},
journal = {Cerebrovascular Diseases},
year = {2026},
pages = {1--9},
doi = {10.1159/000552209}
}
EUVIMED